{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:27:19Z","timestamp":1769689639645,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The reemergence of yellow fever virus (YFV) in Africa and Brazil, and massive vaccine campaigns triggered to contain the outbreaks, have raised concerns over blood transfusion safety and availability with increased risk of YFV transfusion\u2010transmitted infections (TTIs) by native and vaccine\u2010acquired YFV. Blood donor deferral for 2 to 4\u2009weeks following live attenuated YFV vaccination, and deferral for travel to endemic\/epidemic areas, may result in blood donor loss and impact platelet component (PC) stocks. This study investigated the efficacy of INTERCEPT Blood System pathogen reduction (PR) with use of amotosalen and ultraviolet A (UVA) light to inactivate high levels of YFV in PCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>MATERIALS<\/jats:title><jats:p>Four units of apheresis platelets prepared in 35% plasma\/65% platelet additive solution (PC\u2010PAS) and 4 units of PC in 100% human plasma (PC\u2010Plasma) were spiked with high infectious titers of YFV (YFV\u201017D vaccine strain). YFV\u201017D infectious titers were measured by plaque assay and expressed as plaque\u2010forming units (PFU) before and after amotosalen\/UVA treatment to determine log reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The mean YFV\u201017D infectious titers in PC before inactivation were 5.5\u2009\u00b1\u20090.1 log PFU\/mL in PC\u2010PAS and 5.3\u2009\u00b1\u20090.1 log PFU\/mL in PC\u2010Plasma. No infectivity was detected immediately after amotosalen\/UVA treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>The amotosalen\/UVA PR system inactivated high titers of infectious YFV\u201017D in PC. This PR technology could reduce the risk of YFV TTI and help secure PC supplies in areas experiencing YFV outbreaks where massive vaccination campaigns are required.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.15673","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T12:05:54Z","timestamp":1579521954000},"page":"622-627","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen\u2010reduction technology"],"prefix":"10.1111","volume":"60","author":[{"given":"Yvette A.","family":"Girard","sequence":"first","affiliation":[{"name":"Department of Microbiology Cerus Corporation  Concord California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Santa Maria","sequence":"additional","affiliation":[{"name":"Department of Microbiology Cerus Corporation  Concord California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-5013","authenticated-orcid":false,"given":"Marion C.","family":"Lanteri","sequence":"additional","affiliation":[{"name":"Department of Scientific Affairs Cerus Corporation  Concord California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408360490497474"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.05.018"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ento.52.110405.091454"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760180278"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760170361"},{"key":"e_1_2_7_7_1","first-page":"34","article-title":"Transfusion\u2010related transmission of yellow fever vaccine virus\u2013California, 2009","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_7_8_1","unstructured":"WHO Library Cataloguing\u2010in\u2010Publication Data Blood donor selection: guidelines on assessing donor suitability for blood donation. ISBN 978 92 4 1548519 (NLM classification: WH 460) 2012 Switzerland."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02279.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.7.2019"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14442"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.12-0603"},{"key":"e_1_2_7_13_1","unstructured":"INTERCEPT\u00ae blood system for platelets \u2010 SPC 00701\u2010AW V3.0. July 17 2018. Available at:https:\/\/intercept\u2010usa.com\/images\/resources\/Package_Inserts\/INTERCEPT_Blood_System_INT2530B_DS_Package_Insert_July2018.pdf."},{"key":"e_1_2_7_14_1","unstructured":"INTERCEPT\u00ae blood system for plasma \u2010 SPC 00333\u2010AW v2.0. August 17 2015. Available at:https:\/\/intercept-usa.com\/images\/resources\/Package_Inserts\/INTERCEPT_Blood_System_Platelets_Plasma_P_Package_Insert-US.pdf"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12713"},{"key":"e_1_2_7_16_1","first-page":"24A","article-title":"Simultaneous inactivation of co\u2010circulating arboviruses through nucleic acid crosslinking","volume":"58","author":"Santa Maria F","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13271"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14161"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82023-0"},{"key":"e_1_2_7_20_1","unstructured":"LopertP AgaG RiceJ et al.Apheresis platelets collected on Trima Accel and stored in Intersol platelet additive solution for 5 and 7\u2009days are comparable for pH and morphology to plasma\u2010stored platelets in vitro. AABB annual meeting Boston 2018."},{"key":"e_1_2_7_21_1","volume-title":"The 2014\u20102015 AABB blood collection and utilization survey report","author":"Rajbhandary S","year":"2018"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15332"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41950-3"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817001200"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.026"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39406-9"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/tru092"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.08.030"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00827-18"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.04.013"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-391"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.01.048"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.015"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw045"},{"key":"e_1_2_7_35_1","unstructured":"U.S Department of Health and Human Services. February: recommendations for donor screening deferral and product management to reduce the risk of transfusion transmission of Zika virus \u2010 guidance for industry. Food and Drug Administration Center for Biologics Evaluation and Research; 2016. [Cited date 02\u2010August 2019]. Available from:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/UCM486360.pdf."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14892"},{"key":"e_1_2_7_37_1","unstructured":"U.S. Department of Health and Human Services. August: revised recommendations for Reducing the risk of Zika virus transmission by blood and blood components guidance for industry. Food and Drug Administration Center for Biologics Evaluation and Research; 2016. [Cited date 02\u2010August 2019]. Available from:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/UCM518213.pdf."},{"key":"e_1_2_7_38_1","volume-title":"Recommendations for Reducing the Risk of Transfusion\u2010Transmitted Babesiosis Guidance for Industry","author":"U.S. Department of Health and Human Services","year":"2019"},{"key":"e_1_2_7_39_1","unstructured":"Food and Drug Administration.Exceptions and Alternative Procedures Approved Under 21 CFR 640.120. 2019. Available at:https:\/\/www.fda.gov\/vaccines-blood-biologics\/regulation-blood-supply\/exceptions-and-alternative-procedures-approved-under-21-cfr-640120."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2405.171609"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32520-0"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479192"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.15673","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15673","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15673","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T01:27:45Z","timestamp":1694050065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/trf.15673"],"URL":"https:\/\/doi.org\/10.1111\/trf.15673","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"2019-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}